SSE Ticker: 600713

Nanjing Pharmaceutical Co., Ltd.

南京医药

Authorized Representative: 周建军

Board: Main A

Industry Classification: Wholesale & Retail

Be resolute! In the era of digital economy, the application field of China's software industry is leading the trend

Post date May 15, 2022 — 17:52 Post Lock

Chaoxun Communications Board Secretary: The loss in 2021 is mainly due to the sharp decline in the performance of the controlled subsidiary and the company's provision for asset impairment losses.

Post date May 13, 2022 — 20:08 Post Lock

11 days and 10 boards, it went crazy! The revenue hit a new high in 5 years, but netizens said: "Chicken feathers in one place, sooner or later!" what happened? -Stock Channel-Hexun.com

Post date May 13, 2022 — 17:30 Post Lock

Watching the market: Hongtao shares and other 6 stocks stopped in seconds CFi.CN Zhongcai Network

Post date May 12, 2022 — 10:35 Post Lock

Nuggets for innovative drugs Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research

Post date May 9, 2022 — 02:16 Post Lock

Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research

Post date May 8, 2022 — 17:33 Post Lock

Policies to provide warmth can be expected to stabilize, the real estate industry is waiting for flowers to bloom-Pyeongchang Real Estate Information Network

Post date May 8, 2022 — 17:01 Post Lock

Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research

Post date May 8, 2022 — 15:50 Post Lock

Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews

Post date May 8, 2022 — 15:50 Post Lock

Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research

Post date May 8, 2022 — 13:24 Post Lock

Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research

Post date May 8, 2022 — 13:23 Post Lock

Policies to provide warmth can be expected to stabilize, and the real estate industry is waiting for flowers to bloom

Post date May 7, 2022 — 17:48 Post Lock

During the in-depth adjustment period, research institutions are keen to tap potential opportunities. Junshi Bio has been "crossed the threshold"! -Hong Kong stocks-financial sector

Post date May 6, 2022 — 15:03 Post Lock

During the in-depth adjustment period, research institutions are keen to tap potential opportunities. Junshi Bio has been "crossed the threshold"! Junshi Biology_Sina Finance_Sina.com

Post date May 6, 2022 — 14:03 Post Lock

During the in-depth adjustment period, research institutions are keen to tap potential opportunities. Junshi Bio has been "crossed the threshold"

Post date May 6, 2022 — 12:53 Post Lock

Zhengyan sees the disk: There should be two major reasons for the emotional preference to buy on dips – yqqlm

Post date May 6, 2022 — 08:38 Post Lock

Yang Delong: The Fed's interest rate hike boots landing multiple policies are good to boost market confidence Fund Channel Hexun Network

Post date May 5, 2022 — 21:49 Post Lock

Hang Seng Index closed down 0.36% at 20793, property stocks were under pressure, Ronshine China (03301) fell 9.38%_ Finance & Economics

Post date May 5, 2022 — 19:45 Post Lock

In 2022, it is difficult to have a job! -News Channel-Hexun.com

Post date May 2, 2022 — 23:52 Post Lock

What are the exclusive Chinese medicine concept stocks in 2022? Exclusive list and ranking of leading Chinese medicine stocks (stock code)

Post date May 2, 2022 — 11:17 Post Lock

Want to see more data? Registered subscribers can see all the data.